Dirithromycin and, to a lesser extent, erythromycylamine and erythromycin directly induced the release of three intragranular enzymes (lysozyme, lactoferrin, and j-glucuronidase) from erythromycylamine (18, 22). Although there are many data suggesting that the preferential intracellular location of these drugs is the phagocytic granule (8, 25, 32), few reports have dealt with the possible consequences of granule trapping on the degranulation process. Engquist, Lundberg, and Peterson (10) reported increased release of proteases by erythromycin-treated neutrophils, whereas Carevic and Djokic (7) observed an inhibition of immune complex-triggered degranulation of human neutrophils by azithromycin and, to a lesser extent, erythromycin.
concentration. Dirithromycin was the most effective. At 120 min, release of lysozyme, 0-glucuronidase, and lactoferrin by macrolide (100 ,uglml)-treated cells, expressed as a percentage of total enzyme content, was, respectively, 58% + 8.3%, 52% 10.7%, and 35% + 5.1% (dirithromycin); 42% + 3.9%, 28% 5.8%, and 10%o 2.2% (erythromycylamine); and 35% 4.0%o, 19%o 4.3%, and 10%o 5.2% (erythromycin) (mean + standard error of the mean of three to eight experiments). The lowest macrolide concentrations which induced significant enzyme release were 10, 100, and 25 ,ug/ml, respectively, for dirithromycin, erythromycylamine, and erythromycin. Furthermore, we obtained evidence of a link between the prodegranulation effects of dirithromycin and erythromycylamine and the intragranular location of these drugs. Indeed, cell-associated drug levels increased for up to 60 min and then plateaued and declined substantially. Increasing the pH from 7 to 9 resulted in a parallel increase in drug uptake and the prodegranulation effect. Finally, when macrolide-treated neutrophils were disrupted by sonication and centrifuged, a correlation was found between lysozyme and ,-glucuronidase activities (both granule markers) and pellet-associated macrolide levels. Taken together, our results suggest that dirithromycin and erythromycylamine concentrate within neutrophil granules and then induce degranulation.
Although macrolides have been used for more than 50 years, very little is known about their possible interference with human cells. For these last 10 years, there has been a renewed interest in such phenomena, because of a better knowledge of the cellular (particularly phagocytic) uptake of these drugs (8, 14, 20) . The enormous cellular accumulation of macrolides (reaching values 30-to 40-fold higher than extracellular levels) is likely to modify cellular activities. Indeed, there is now substantial in vitro evidence of a direct effect of these drugs on phagocyte functions (1, 15, 19) , although its clinical relevance is still a matter of debate. Most of the relevant literature points to macrolide-induced inhibition of phagocyte oxidative metabolism, essentially with 14-membered ring macrolides, particularly roxithromycin (1, 15, 23) , dirithromycin, and erythromycylamine (18, 22) . Although there are many data suggesting that the preferential intracellular location of these drugs is the phagocytic granule (8, 25, 32) , few reports have dealt with the possible consequences of granule trapping on the degranulation process. Engquist, Lundberg, and Peterson (10) reported increased release of proteases by erythromycin-treated neutrophils, whereas Carevic and Djokic (7) observed an inhibition of immune complex-triggered degranulation of human neutrophils by azithromycin and, to a lesser extent, erythromycin.
We have previously reported that dirithromycin and erythromycylamine (the hydrolysis product of dirithromycin) are avidly concentrated by human neutrophils (26) . The likely mechanism underlying this uptake is trapping by protonation inside acidic cell compartments such as azurophilic granules.
In this study, we investigated the relationship between macrolide uptake and the neutrophil degranulation process.
Erythromycin, the leading macrolide antibiotic, was chosen as the standard of comparison.
MATERIALS AND METHODS
Dirithromycin, erythromycylamine, and the radiolabelled drugs 3H-dirithromycin (20 mCi/mg; 0.05-mg/ml solution in 7:3 ethanol-water) and "4C-erythromycylamine ( Human neutrophils were obtained from heparinized venous blood of volunteers by Ficoll-Paque centrifugation followed by 2% dextran sedimentation and hypoosmotic lysis of residual erythrocytes. The viability, measured by the release of lactate dehydrogenase, and purity of the final preparation were greater than 99 and 95%, respectively.
Stimulating agents. Formyl-methionyl-leucyl-phenylalanine (FMLP) (5 x 10-6 M), phorbol myristate acetate (PMA) (100 ng/ml), and calcium ionophore (A23187) (10-' M) were used as comparative stimuli of degranulation by cytochalasin Btreated neutrophils (5 jig/ml, for 5 min).
Degranulation studies. Neutrophil degranulation was measured by the release of three enzymes: ,B-glucuronidase (a marker of azurophilic granules), lactoferrin (a marker of specific granules), and lysozyme (which is located in both granule subsets). Lactate dehydrogenase (LDH) release was also measured as an index of neutrophil viability, since this (24) . The amount of LDH was assayed by the spectrophotometric measurement (X = 340 nm) of the consumption of ,B-nicotinamide dinucleotide during the conversion of pyruvate to lactate (4) .
In standard experiments, human neutrophils were incubated at 37°C for 25 min in the presence of either the drugs (100 p,g/ml), DMSO (1%), or HBSS plus cytochalasin B (5 ,ug/ml); controls included polymorphonuclear leukocytes incubated in the presence of DMSO plus cytochalasin B for 10 min and then stimulated with FMLP. After incubation, cells were centrifuged at 400 x g for 10 min, and enzyme activities were measured in the pellet and in the supernatant. Enzyme release was expressed as the percentage of enzyme activity in the supernatant relative to that in the sum (pellet plus supernatant). The positive control was activity in a cell lysate obtained by sonication (three 15-s bursts at 30% power from a Fisher sonic dismembranator set at 4°C) in the presence of 0.1% Triton X-100, which induced optimal enzyme recovery (results not shown). Activity in the sum (pellet plus supernatant) did not differ from overall activity measured in the cell lysate. We also verified that the three macrolides (in amounts up to 100 p,g/ml) did not directly modify the enzyme activities of a cell lysate. Degranulation kinetics were studied by using neutrophils pretreated for 5 min with DMSO with or without cytochalasin B before the addition of the drugs or the stimuli (FMLP, A23187, or PMA) for 5 to 180 min. Experimental conditions included variations in the pH of the medium from 7 to 9 and in the extracellular concentration of the drugs (10 to 100 ,ug/ml).
Dirithromycin and erythromycylamine uptake. The uptake of both drugs by neutrophils has been extensively described elsewhere (26) . Briefly, neutrophils (2.5 x 106) were incubated with each drug before centrifugation through a water-impermeable silicone-paraffin oil barrier. The cell pellet was counted, and radioactivity associated with the neutrophils was determined as ng/2.5 x 10' cells by using standard dilution curves run in parallel. The uptake of both drugs was measured in the experimental conditions used for the degranulation studies (i.e., 100-.pg/ml external concentration and incubation from 5 to 180 min, with or without cytochalasin B). In further experiments, dirithromycin uptake was studied by using neutrophils pretreated for 10 min with the following stimuli: PMA (100 ng/ml), A23187 (10-6 M), or FMLP (5 x 10-6 M) in the presence of cytochalasin B (5 ,ug/ml).
Cellular location of dirithromycin and erythromycylamine. Drug-loaded neutrophils (30 min, 100 ,ug/ml) were sonicated (three 15-s bursts in the presence of 0.1% Triton X-100 or three 5-s bursts in buffer without Triton X-100). After 10 min of centrifugation at 400 x g to remove unbroken cells and nuclei, the supernatants were centrifuged at 100,000 x g. Lysozyme, ,B-glucuronidase, and LDH activities and radioactivity in the supernatants and the membrane and granule pellets were measured. In other experiments, sucrose (0.73 M) was added to protect granules from disruption during sonication (three 10-s and three 15-s bursts). After centrifugation at 400 x g, the supernatants were recovered and further centrifuged at 17,000 x g; the granule pellet was resuspended in citrate buffer (pH 5.5; a pH close to the intragranular pH [29] (15 experiments), and 34% ± 1.8% (35 experiments), respectively, for ,-glucuronidase, lactoferrin, and lysozyme. After 25 min of incubation with dirithromycin, there was a slight but significant increase in release of lysozyme, ,B-glucuronidase, and lactoferrin (Table  1) . Although erythromycylamine and erythromycin exerted similar effects, this was significant only for release of erythromycin and lysozyme during this short incubation period, possibly because of the small number of experiments. LDH activity in the supernatants of control and macrolide-treated cells was less than 5%, indicating that neutrophil viability was not altered by either treatment.
(ii) Kinetics of enzyme release induced by macrolides. Since dirithromycin and erythromycylamine display time-dependent uptake kinetics, we assessed the influence of incubation time (Fig. 1A and B) . Dirithromycin and, to a lesser extent, erythromycylamine and erythromycin induced the release of lysozyme and ,-glucuronidase in a time-dependent manner ( Fig. 1A and B) . A similar pattern was obtained in the case of lactoferrin (data not shown). After a 120-min incubation period, dirithromycin induced the release of 35% ± 5.1% of lactoferrin, compared with the control value of 6% ± 2.5% for neutrophils in 1% DMSO (P < 0.02, six experiments), whereas erythromycylamine and erythromycin induced the release of only 10% ± 2.2% and 10% ± 5.2% of lactoferrin (five experiments). LDH release was not significantly altered over the 3-h incubation period (mean percent release ± 1 standard deviation of three experiments: 6.5% ± 2.5%; 4.5% ± 0.7%; 7.5% ± 2.1%; 5.5% ± 3.5%; and 5.0% ± 1.4%, respectively, for DMSO, dirithromycin, erythromycin, erythromycylamine, and HBSS).
Optimal FMLP-induced release (about 40% lysozyme and 20% ,3-glucuronidase) was observed in the first 10 min ( Fig. 2A  and B ). PMA and calcium ionophore stimulation induced a time-dependent release of lysozyme, reaching values similar to those obtained with dirithromycin at 180 min. A similar picture was observed in the case of ,-glucuronidase release after A23187 treatment. PMA did not induce significant release of 3-glucuronidase at 60 min, but slight release occurred at 180 min (Fig. 2B) . LDH release in the presence of the stimuli was less than 5% over the 3-h incubation period, except for PMA at 180 min (15% ± 4.2%; mean, ± 1 standard deviation, of three experiments).
(iii) Concentration-dependent stimulation of enzyme release by macrolides. The effect of macrolides (10 to 100 ,uglml) on the release of lysozyme and 3-glucuronidase was measured after 180 min of incubation ( (26) . Similar effects are known to occur with erythromycin (9). We therefore investigated whether modifications in the pH modified the effects of macrolides on neutrophil degranulation. Increasing the pH from 7 to 9 resulted in a significant increase in the release of lysozyme and 3-glucuronidase ( Fig. 3A and B resented, respectively, 52% ± 7.4% and 63% ± 4.2% (four experiments) of overall enzyme content, while pellet-associated drugs represented 23% ± 1.3% (dirithromycin, five experiments) and 21% (erythromycylamine, one experiment) of the total. When sucrose was included in the medium (two experiments), 67% ± 2.5% and 74% ± 3.0% of lysozyein activity were associated with the pellet, depending on sonication conditions, while pellet-associated dirithromycin and erythromycylamine represented 51% and 65% and 33% and 49%, respectively. Whatever the e'xperimental conditions, pellet-associated LDH (a cytoplasmic marker) was less than 5%. The correlations between lysozyme activity and concentrations of both dirithromycin and erythromycylamine were significant (r = 0.927, P = 0.008 for dirithromycin; r = 0.928, P = 0.000 for erythromycylamine). Figure 4 shows the individual values of pellet-associated enzyme activities and macrolide content as percentages of the total (pellet plus supernatant). When lysozyme and 3-glucuronidase activities were less than 20%, the amount of drugs in the pellet was negligible; above this value, there was a parallel increase in both drug content and enzyme activities in the pellet.
(vii) Consequences of degranulation for the determination of dirithromycin and erythromycylamine uptake by macrolides. In a previous paper (26), we analyzed the time dependence of the uptake of both drugs at concentrations up to 10 ,ug/ml (dirithromycin) and 50 ,ug/ml (erythromycylamine).
Since these concentrations do not induce neutrophil degranulation, there was a time-dependent accumulation of both drugs for up to 180 min. Here, we used the high concentration of 100 ,ug/ml, which induces neutrophil exocytosis and obtained strikingly different results (Fig. 5) . Both drugs were accumulated time dependently, for up to 30 min (dirithromycin) and 60 min (erythromycylamine). This accumulation was followed by a plateau and, in the case of dirithromycin, a decrease during the last 60 min. When neutrophils were pretreated with cytochalasin B before drug uptake was measured, there were no major differences between the two treatments for up to 60 min of incubation; then there was a substantial decrease in cellassociated macrolides in the cytochalasin B-treated group compared with controls, and cell-associated dirithromycin was no longer detectable at 3 h (Fig. 5) . Furthermore, in two complementary experiments, we studied dirithromycin uptake (Fig. 4) The possibility that cytochalasin B alone increased macrolide efflux from neutrophils warrants further study. The ability to induce neutrophil degranulation does not seem to be specific to the macrolides tested here. Preliminary data from our laboratory indicate that similar properties are observed with clarithromycin and roxithromycin (21), two 14-membered ring macrolides which are also heavily concentrated by phagocytes (17) , possibly inside azurophilic granules (8) . Azithromycin, an azalide reported to display tremendous intraphagocytic accumulation by protonation trapping in lysosomes (32) , has been shown to decrease the extracellular release of neutrophil intragranular enzymes (7 (6, 11) . In the case of common pathogens which trigger phagocytosis and do not inhibit phagolysosomal fusion, the intragranular location of these drugs may concur with their bioactivity (against Staphylococcus aureus, Streptococcus pneumoniae, etc.) (2, 3, 27) . However, the reasons for this bioactivity are less clear in the case of pathogens located in phagosomes, such as Legionella spp., Mycobactenium spp., Chlamydia spp., etc.), against which macrolides are active in vitro and in clinical use (6, 25, 28) . The possibility that the prodegranulation activity of some macrolides counteracts the antidegranulation effect of some bacteria could explain this discrepancy.
The mechanism underlying this prodegranulation effect is unclear, but macrolides are weak bases and could thus increase lysosomal pH. Alkalinization has been shown to promote neutrophil degranulation, a phenomenon obtained with chloroquine (an antimalarial, weak base, which is concentrated within neutrophil granules) (13) , bafilomycin (a macrolide antibiotic which inhibits V-ATPase pumps responsible for intragranular acidification) (5, 30) , and monensin and nigericin (two cationic ionophores acting on the alkali ion/H+ antiport at the granule membrane) (12) . Whether macrolide-induced granular alkalinization is the principal mechanism or only a step leading to other cellular changes is currently under study.
